Beijing, China — November 7, 2025 — Chongqing Precision Biotech Co., Ltd. today announced that Puzolcabtagene Autoleucel Injection (pCAR-19B) has received marketing approval from the National Medical Products Administration (NMPA).

On March 31, 2025, Precision Biotech Attended Chongqing Pharmaceutical Innovation Conference and Made Work Report

On March 31, 2025, Precision Biotech Attended Chongqing Pharmaceutical Innovation Conference and Made Work Report

On March 25th, Prof. Cheng Qian, Chairman and Chief Scientist of Chongqing Precision Biotech, has been on the list for 4 consecutive years due to his outstanding academic influence as a unique academic leader in the field of clinical medicine.

On February 26, 2025, the ceremony for the release of the top ten scientific and technological innovations of the Western (Chongqing) Science City in 2024 under the slogan of “Scientific and Technological Innovation and Strengthening the City with Talents” was held at the Science Hall of Chongqing. Precision Biotech's self-developed CAR-T therapy product for childhood leukemia- Priscabtagene Autoleucel Injection was successfully selected.